Results: There were no significant differences in baseline characteristics except angulated lesion (1st DES vs. 2nd DES: 12.3% vs. 29.2%, p < 0.001), burr-to-artery ratio (0.62 vs. 0.59, p < 0.001), and IVUS use (42.8% vs. 81.7%, p < 0.001). In all patients, no significant differences were observed between 2 groups in the restenosis and TLR rates (21.2 vs. 14.2%, p ¼ 0.12 and 17.1% vs. 11.7%, p ¼ 0.22, respectively). However, the restenosis and TLR rates of 2nd DES were significantly lower than those rates of 1st DES in non-HD patients (19.0% vs. 7.9%, p ¼ 0.015 and 13.9% vs. 5.6%, p ¼ 0.047, respectively). In contrast, those rates were similar between 2 groups in HD patients (30.2 vs. 32.3%, p ¼ 1.0 and 30.2% vs. 29.0%, p ¼ 1.0, respectively). Table shows quantitative angiographic outcomes. Conclusions: The mid-term angiographic results of 2nd DES might be superior to those of 1st DES in non-HD patients treated with DES implantation following RA.
Background: Differences in enrollment criteria and protocol requirements are thought to affect patient representation and outcomes from premarket and postmarket surveillance (PMS) . We assessed differences between premarket vs. PMS trials assessing implantation of the Endeavor-zotarolimus eluting stent (E-ZES). Methods: We analyzed data from 2132 and 4357 E-ZES treated subjects (ENDEAVOR premarket and PROTECT PMS trials, respectively) . We analyzed differences in 3-year outcomes and adjusted them for differences in baseline characteristics. Results: The two groups differed significantly in baseline characteristics. However, the rates of 3-year major adverse cardiac event (MACE), major adverse cardiac and cerebrovascular event (MACCE) and target vessel failure (TVF), were similar (12.67% vs. 13.88%, p¼0.191; 11.88% vs. 12.68%, p¼0.369; and 13.81% vs. 13.01%, p¼0.419, respectively) . PMS trials had less clinically driven target vessel revascularizations (CD-TVR, p<0.001) and more myocardial infarctions (MI, p¼0.005). Differences emerged at 8 moths and immediately post-procedurally, respectively. After propensity score adjustment, CD-TVR rates no longer differed significantly (HR 0.72, 95% CI 0.51-1.01).
Conclusions: Premarket and PMS trials assessing E-ZES implantation had similar 3-year composite outcomes. Differences in CD-TVR were attributed to different protocol requirements and in MIs to different outcome definitions. It is yet to be determined if these settings reflect everyday practice.
TCT-205
One year outcomes of percutaneous coronary intervention with a modern drug-eluting stent in patients with moderate and severe coronary calcification: A pooled analysis from the Nobori-2 and e-Nobori all-comer registries Gert Richardt 1 , Mohamed El-Mawardy 1 , Dmitriy S. Sulimov 1 , Mohamed Abdel-Wahab 1 1 Heart Center, Segeberger Kliniken, Bad Segeberg, Germany Background: Percutaneous coronary intervention (PCI) of moderate and severely calcified lesions has been described as a predictor of worse outcomes when baremetal stents or first-generation drug-eluting stents (DES) have been used. Little is known about the impact of coronary calcification on outcome after PCI with modern DES. Methods: 14,134 patients treated with a biolimus A9-eluting stent with a biodegradable polymer (Nobori, Terumo, Japan) were pooled from 2 all-comer registries (Nobori-2 and e-Nobori). An independent clinical event committee adjudicated all adverse events and an independent corelab analyzed baseline and adverse events' angiograms. Patients were divided into 2 groups based on whether or not PCI was performed on moderate/severely calcified lesions. Target lesion failure (TLF), defined as cardiac death, target vessel-related myocardial infarction and target lesion revascularization, and stent thrombosis were assessed at 1 year. Results: Overall, 4321 patients (30.6%) had moderate/severe coronary calcification. Patients with calcified lesions were older and had a higher rate of diabetes mellitus, hypertension, renal failure, peripheral arterial disease and previous bypass surgery, but less commonly presented with an acute coronary syndrome. Patients with calcified lesions more commonly required multivessel treatment and needed longer stents. Preand post-dilatations were more often performed in the calcified lesions group. Rotational atherectomy or cutting balloons were used in only 5.49%. Preliminary data at 1-year follow-up (currently available in 9,089 patients) revealed low rates of TLF and stent thrombosis, but both were significantly higher in patients with moderate/ severe calcification (TLF in 5.03% vs. 2.83%, p<0.001, stent thrombosis in 0.72% vs. 0.34%, p¼0.03). By multivariate analysis, the presence of moderate/severe calcification was a strong independent predictor of TLF at 1-year (OR1.77, 95%CI 1.23-2.55, p¼0.002). Conclusions: Moderate/severe coronary calcification independently predicts increased rates of TLF at 1-year after PCI with the biolimus A9-eluting Nobori stent, but overall stent performance remains excellent and event rates are surprisingly low. Background: This study was performed to assess angiographic outcomes of newer generation drug-eluting stent (NDES) [everolimus-(EES) or resolute zotarolimuseluting stents (R-ZES)] versus sirolimus-eluting stents (SES) for long or diabetic coronary artery disease. Methods: Patients level data from three randomized trials (Long-DES III, IV and ESSENCE-DIABETES) were pooled to estimate angiographic efficacy of EES or R-ZES versus SES. A total of 1,250 patients underwent EES or R-ZES (NDES group, n¼623) and SES (SES group, n¼627). We evaluated angiographic restenosis after DES implantation at follow-up duration. Results: Follow-up angiography was done in 919 patients (73.5%). In-stent (3.0% vs. 4.4%, p¼0.28) and in-segment restenosis (5.0% vs. 5.2%, p¼0.86) was also statistically not different between NDES vs. SES group. In-segment restenosis was similar between NDES vs. SES group in diabetics (3.9% vs. 6.7%, p¼0.22), > 30 mm long stent implantation patients (6.9% vs. 6.0%, p¼0.64), and 2.5 mm small vessel disease (6.3% vs. 8.7%, p¼0.50). However, lesion length > 40 mm showed significantly higher angiographic restenosis compared to lesion length 40 mm in both stents groups (NDES: 10.2% vs. 3.2 %, p¼0.003: SES: 9.0 % vs. 3.9%, p¼0.03). Conclusions: Newer generation DES showed comparable angiographic outcomes with SES in patients at high risk of restenosis and effectively reduced angiographic restenosis across all high risk lesion subsets, but their angiographic efficacies were attenuated in > 40 mm lesion length in both stent groups. TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
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